HC Wainwright Forecasts Biodesix's Q3 Earnings (NASDAQ:BDSX)

Key Points

• HC Wainwright lowered Biodesix’s Q3 2026 EPS estimate to a loss of $0.75 per share from $0.74, while maintaining a Buy rating and $27 price target.
• Biodesix recently reported a quarterly loss of $0.71 per share, beating the $0.90 consensus estimate, with revenue of $26.86 million versus expectations of $26.03 million.
• Analyst sentiment remains generally positive, with the stock carrying a Moderate Buy consensus rating and an average target price of $28.67; institutional investors own 20.96% of shares.

Biodesix, Inc. (NASDAQ:BDSX - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Biodesix in a report released on Thursday, August 6th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.75) per share for the quarter, down from their prior forecast of ($0.74). HC Wainwright has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for Biodesix's current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Biodesix's Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.72) EPS, Q1 2027 earnings at ($0.65) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($1.57) EPS.

Biodesix (NASDAQ:BDSX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The firm had revenue of $26.86 million during the quarter, compared to analyst estimates of $26.03 million.

BDSX has been the subject of several other research reports. Roth Capital assumed coverage on Biodesix in a research report on Wednesday, June 24th. They set a "buy" rating and a $32.00 target price for the company. Weiss Ratings upgraded Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, June 12th. Finally, Canaccord Genuity Group upped their price objective on Biodesix from $22.00 to $27.00 and gave the company a "buy" rating in a research report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $28.67.

Biodesix Stock Performance

Shares of NASDAQ:BDSX opened at $23.50 on Monday. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 5.12. Biodesix has a 12 month low of $5.26 and a 12 month high of $25.00. The company has a market capitalization of $247.93 million, a price-to-earnings ratio of -7.41 and a beta of 0.56. The firm's 50-day moving average is $19.65 and its 200 day moving average is $15.75.

Hedge Funds Weigh In On Biodesix

A number of hedge funds have recently added to or reduced their stakes in BDSX. BlackRock Inc. bought a new stake in shares of Biodesix during the second quarter valued at approximately $970,000. AIGH Capital Management LLC purchased a new position in Biodesix during the 2nd quarter worth $15,296,000. GSA Capital Partners LLP bought a new stake in Biodesix during the 2nd quarter valued at $1,060,000. Walleye Capital LLC bought a new stake in Biodesix during the 2nd quarter valued at $1,679,000. Finally, Stempoint Capital LP purchased a new stake in shares of Biodesix in the 1st quarter worth $1,015,000. 20.96% of the stock is currently owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source